The role of the complement system in diabetic nephropathy

Allan Flyvbjerg
DOI: https://doi.org/10.1038/nrneph.2017.31
IF: 42.439
2017-03-06
Nature Reviews Nephrology
Abstract:Key PointsDiabetic nephropathy has severe individual and societal consequences, owing to its high morbidity, mortality and health-care costsDespite the availability of anti-glycaemic, renoprotective and antihypertensive agents, diabetes mellitus remains the most common cause of end-stage renal disease in developed countriesNew biomarkers that can identify patients at risk of diabetic nephropathy are needed, as well as new agents that directly target the pathogenic pathways of diabetic nephropathyGrowing evidence suggests that the complement system has a pathogenic role in the development of diabetic nephropathyMannose-binding protein is a strong biomarker of diabetic nephropathy in patients with type 1 diabetes mellitus (T1DM) and T2DM; H-ficolin might be useful to identify patients with T1DM at risk of persistent microalbuminuriaInhibiting specific components of the complement system might be an effective therapeutic strategy to treat diabetic nephropathy
urology & nephrology
What problem does this paper attempt to address?